drugset / Trial / NCT05940545
UMIT-1 Trial Favipiravir & Ribavirin for the Treatment of CCHF
RandomizedParallel-groupOpen-labelTreatment
Summary
UMIT-1: A Randomised Phase Ib Study to Determine the Phase II dose and to Evaluate the Safety and Efficacy of intravenous (IV) Favipiravir \& Ribavirin for the Treatment of CCHF
Timeline
- Start
- 2023-07-12
- Primary completion
- 2023-09-30
- Completion
- 2023-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Favipiravir | Small molecule | 800 mg | Intravenous |
| Comparator | Favipiravir | Small molecule | 1200 mg | Intravenous |
| Comparator | Ribavirin | Small molecule | — | — |